Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis

Pediatric anticoagulant guidelines for venous thromboembolism (VTE) are mainly based on extrapolation from trials in adults, with low levels of evidence from the pediatric population. However, anecdotal evidence in neonates resulted in suggested (Grade 2 C recommendations) treatment durations of between 6 weeks and 3 months for both central venous catheter-related VTE (CVC-VTE) and other VTE (e.g. renal vein thrombosis or cerebral sinus venous thrombosis) [1]. In clinical practice, shorter durations of treatment (i.e. < 3 months) are frequently used in children beyond the neonatal age group, presumably related to the difficulties in delivering anticoagulation using currently available drugs.

Performing clinical studies in young children with VTE is challenging for a variety of reasons. First, VTE is a relatively rare condition in children with reported incidences being approximately 100 times lower than in adults, requiring large and expensive collaborative efforts to recruit even a low number of children [2‐8]. Second, young children with VTE represent a sick population since their VTE is often hospital acquired, largely due to more aggressive treatments of serious and life-threatening comorbidities [9]. Third, international restrictions on blood volumes that can be drawn for purposes other than routine medical care, limit participation of those with a low bodyweight [10]. Finally, parental consent is often difficult to obtain in young children with acute serious conditions in combination with a short decision window.

The EINSTEIN-Jr phase III study (clinicaltrials.gov NCT02234843) is a randomized study comparing the efficacy and safety of bodyweight-adjusted rivaroxaban with standard anticoagulation for the treatment of acute VTE in children [11]. The study started in 2014 with children aged 12–18 years and, in a staggered approach, continued with those aged 6–12 years, and 2–6 years. Study treatment is given for 3 months with the option to continue treatment in 3 months increments, up to a total duration of 12 months, with a repeat imaging test scheduled at month 3. During the last phase of the EINSTEIN-Jr. study, recruitment will be opened for neonates and infants younger than 2 years.

In this retrospective analysis, we describe the presentation, therapeutic management, and outcomes observed in children younger than 2 years who received care for VTE in recent years. In addition, we assessed their potential eligibility for enrolment into the EINSTEIN-Jr trial.

A group of EINSTEIN-Jr. investigators from 12 institutions in North America, Europe and Israel collected data from their institutions for the period 2011–2016 for children younger than 2 years with VTE and described the diagnosis of VTE at the time of presentation, if anticoagulant therapy was instituted, and the type of therapy. In addition, they assessed if children had developed recurrent VTE.

The potential eligibility for the EINSTEIN-Jr study of children with VTE seen in 2016 was done by determining the proportion of children who would have passed the screen of inclusion and exclusion criteria, as proposed in the protocol (Table 1). Then, investigators indicated whether or not they would have considered each child for inclusion into the study. This question was intended to capture additional factors not specified by the eligibility criteria, such as the child being considered too ill, or because the child was discharged to a remote location.

Data that was collected from the records included year of diagnosis, site of venous thrombosis, gestational age and bodyweight at birth, age at diagnosis, type of anticoagulant treatment (if given), and occurrence of recurrent VTE. For the purposes of this study, short duration treatment was defined a priori as < 6 weeks for those CVC-VTE and < 3 months for those with non-CVC-VTE. In addition, other details available to address the set of eligibility criteria were collected. To better describe factors which may contribute to children being rendered ineligible for participation in EINSTEIN-Jr, the cumulative loss of children for the year 2016 is depicted in a funnel diagram. For the latter analysis, children for whom missing data was reported were assumed to have fulfilled criteria.

The search strategies to identify children with VTE varied between the sites and consisted of review of anticoagulation prescription records from the hospital pharmacy database, the investigator’s referral records, discharge letters, and department’s patient records. At a single site, data was collected for the first 2 months of each year and, therefore, does not represent a complete sample over the time period 2011–2016.

The study was conducted by Competitive Drug Development International Ltd. (CDDI), London, United Kingdom in collaboration with Bayer AG. The protocol was approved by the Institutional Review Board or Ethics Committee of each participating center, when required.

This study demonstrated that two-thirds of children with VTE younger than 2 years developed their VTE as a complication of the use of central catheters, with the highest incidence of VTE in the first month of life. In contradistinction to what might be expected given the current pediatric anticoagulant guidelines [1], this snapshot of contemporary clinical practice revealed that no anticoagulant therapy was given to one-tenth of children, whereas one-fourth received a short duration of anticoagulant therapy, respectively. Recurrent VTE rates without anticoagulation, during anticoagulation or shortly after its discontinuation seem comparable to those observed in adults [27‐30].

The reasons behind non-adherence to the international guidelines for many children in this analysis was beyond the scope of this study, however, it is likely that it is related to the absence of any randomized, quasi-randomized, or cluster-randomized controlled trials in neonates or young children with a diagnosis of thrombosis [31]. In addition, we postulate that it could be related to the presence of serious illnesses contraindicating the use of anticoagulants, apprehension of bleeding risk in the neonatal period, the presentation with minimal clots, and the practice of repeat ultrasound imaging to guide duration of treatment, with continuation of anticoagulation only if recanalization has failed. Whether resolution on ultrasound represents true cure, and abolition of risk of recurrence for catheter or non-catheter related VTE remains to be determined.

The most important reasons which could render children younger than 2 years ineligible for the EINSTEIN-Jr study were a gestational age of less than 37 weeks at birth, a bodyweight less than 2600 g and the requirement for at least 10 days of oral feeding. As a result, an inclusion rate of approximately 0.5 young child per year per site can be anticipated in EINSTEN-Jr. Use of short and flexible treatment durations carries potential to increase recruitment rates and appears to be in keeping with current practice for anticoagulant therapy duration, but raises the spectre of elevating expected recurrence rates.

Based on this analysis, we did not modify the screen of eligibility criteria of young children; however, we decided that young children with CVC-VTE could be treated for a minimum of 4 weeks. Although a treatment duration of less than 3 months carried the potential for increased recruitment in children younger than 2 years who had non-CVC-VTE, we decided to keep the required treatment durations at least 3 months since it is well documented that shorter periods of anticoagulation are associated with increased rates of recurrent VTE in adults [12‐14]. We believe that these treatment durations will allow physicians to consider most young children with clinically significant VTE for our study. If physicians consider prolongation of anticoagulation beyond these required durations, the protocol will allow continuation of treatment for CVC-VTE in 1-month increments (up to a total duration of 3 months), and continuation of treatment for other VTE in 3-months increments (up to a total duration of 12 months). Also, repeated imaging will be done at the end of the 1-month treatment period in children with CVC-VTE and at the end of the 3-months treatment period in children with other VTE.

Neonates and young children with thrombosis often have CVC-VTE, and often receive no or only short durations of anticoagulant therapy. Recurrent VTE rates without anticoagulation, during anticoagulation or shortly after its discontinuation seem comparable to those observed in adults. Longitudinal studies to better understand the natural history of VTE in young children are urgently required. Once the population that definitely requires treatment is identified, then randomized clinical trials evaluating anticoagulant strategies are urgently needed to address the question of dose and duration, and to evaluate its benefit/risk in the treatment of VTE in young children. However, recruitment will be very challenging. Allowing short and flexible treatment durations into the EINSTEIN-Jr. phase III study could potentially increase recruitment and permit a representative population of current practice.